BioTech Medics, Inc. Announces Development of New & Improved BioBody Balance(R) Energy Nano-Spray

SOUTHLAKE, TX--(Marketwire - September 15, 2011) -

BioTech Medics Inc. (PINKSHEETS: BMCS) announced today that it has entered into an agreement with NanoSynergy of Florida to reformulate BioTech’s existing BioBody Balance® Supplement Drink which has sold over $5 million in gross sales into a new and improved BioBody Balance Energy Nano-Spray for Life™.

BIOBODY BALANCE® is a new and unique 21st Century product with over 10 years research and development. Our demanding 24-7 lifestyle can drain the body of the physical resources needed to meet each day’s challenges. BioBody Balance Energy Nano-Spray For Life is a caffeine-free high quality pharmaceutical grade vitamin supplement with over 14 vitamins, minerals, amino acids with an aloe vera base for those who are concerned with boosting energy, alertness and general fatigue naturally without artificial stimulants. BioBody Balance ingredients have been clinically tested to demonstrate they help your body restore its natural energy, strength, stamina and defenses.

“What is unique about the ‘nanosynergy’ process is that the molecular make-up of the product is reduced to molecules the size of human red blood cells,” said Keith Houser CEO. “BIOBODY BALANCE® is superior because the product is sprayed sublingually ‘under your tongue.’ Sublingual administration has certain advantages over oral caffeine drinks because the product is absorbed faster. Being sublingual ensures that our product will only be degraded by salivary enzymes before entering the bloodstream.”

“BioBody Balance is more economical as our suggested retail price is less than $.83 per serving compared to a caffeine energy drink at $2.00 or more per serving,” added Mr. Houser.

The product is expected to be available by the end of this quarter. A new web site is under development at www.biobodybalance.net.

Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the “Act”). In Particular, when used in the preceding discussion, the words “expected” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed. The FDA has not evaluated the BioBody Balance statements above. BioBody Balance is not intended to diagnose, treat or cure any disease.